Detalles de la búsqueda
1.
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.
Lancet Oncol
; 23(11): 1367-1377, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-36183733
2.
Feasibility and efficacy of a supervised home-based physical exercise program for metastatic cancer patients receiving oral targeted therapy: study protocol for the phase II/III - UNICANCER SdS 01 QUALIOR trial.
BMC Cancer
; 20(1): 975, 2020 Oct 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33036567
3.
Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer.
Eur J Cancer
; 157: 415-423, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34597975
4.
Real-World Experience of Bevacizumab as First-Line Treatment for Ovarian Cancer: The GINECO ENCOURAGE Cohort of 468 French Patients.
Front Pharmacol
; 12: 711813, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34616296
Resultados
1 -
4
de 4
1
Próxima >
>>